Navigating Ocular Health in the Age of Antibody-drug Conjugates
This article discusses the impact of a new class of targeted drugs for cancer therapy, known as antibody-drug conjugates (ADCs), on ocular health.
Key Points
- ADCs allow targeted delivery of a highly potent anti-cancer agent to the tumor with limited damage to surrounding healthy cells.
- Each ADC carries its own set of toxicities.
- Mirvetuximab soravtansine-gynx injection 100 mg offers a new option for patients with certain types of ovarian cancer.
- Most mirvetuximab-associated ocular adverse events are low-grade corneal events that are resolvable with supportive care for symptoms and dose modifications when indicated.
- An eye care management plan for mirvetuximab therapy is reflected in US product labeling to include the use of pre-treatment eye drops, ophthalmic monitoring, and dose modifications by the patient’s oncologist.
![](https://hcn.health/wp-content/uploads/2023/09/did-you-know.png)
Epithelial ovarian carcinoma (EOC) is estimated to cause 13,270 deaths in the United States in 2023.
More on Ovarian Cancer